The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

OncoGenex Pharmaceuticals Inc

Nasdaq: OGXI(*D)
Last

(U.S.) $0.55

Today's change0.00 0.00%
Updated January 23 3:55 PM -5GMT. Delayed by at least 15 minutes.
 

OncoGenex Pharmaceuticals Inc

Nasdaq: OGXI(*D)
Last

(U.S.) $0.55

Today's change0.00 0.00%
Updated January 23 3:55 PM -5GMT. Delayed by at least 15 minutes.

OncoGenex Pharmaceuticals Inc closed at (U.S.)$0.55.

Over the last five days, shares have lost 8.43% and 26.75% over the last 52 weeks. This security has underperformed the S&P 500 by 45.54% during the last year.

Key company metrics

  • Open(U.S.) $0.55
  • Previous close(U.S.) $0.55
  • High(U.S.) $0.58
  • Low(U.S.) $0.52
  • Bid / Ask(U.S.) $0.00 / (U.S.) $0.78
  • YTD % change+9.90%
  • Volume161,143
  • Average volume (10-day)1,272,232
  • Average volume (1-month)834,160
  • Average volume (3-month)629,690
  • 52-week range(U.S.) $0.33 to (U.S.) $1.42
  • Beta1.77
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.54
Updated January 23 3:55 PM -5GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-144.42%

Although this company's net profit margin is negative, it is above the industry average and implies that OncoGenex Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.44%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue0236
Total other revenue--------
Total revenue0236
Gross profit--------
Total cost of revenue--------
Total operating expense49710
Selling / general / administrative2223
Research & development4557
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)-110--
Other operating expenses, total--------
Operating income-4-6-4-3
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-4-7-4-2
Income after tax-4-7-4-2
Income tax, total--------
Net income-4-7-4-2
Total adjustments to net income--------
Net income before extra. items-4-7-4-2
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-4-7-4-2
Inc. avail. to common incl. extra. items-4-7-4-2
Diluted net income-4-7-4-2
Dilution adjustment--------
Diluted weighted average shares30303030
Diluted EPS excluding extraordinary itemsvalue per share-0.12-0.23-0.12-0.06
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.17-0.18-0.11-0.06